Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001917950 | SCV002169761 | uncertain significance | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | 2022-06-27 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 376 of the HMGCS2 protein (p.Thr376Ile). This variant is present in population databases (rs772359110, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with HMGCS2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004041719 | SCV004884693 | uncertain significance | Inborn genetic diseases | 2023-10-28 | criteria provided, single submitter | clinical testing | The c.1127C>T (p.T376I) alteration is located in exon 6 (coding exon 6) of the HMGCS2 gene. This alteration results from a C to T substitution at nucleotide position 1127, causing the threonine (T) at amino acid position 376 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |